4//SEC Filing
Harris Matthew Scott 4
Accession 0001104659-25-008772
CIK 0001326190other
Filed
Feb 2, 7:00 PM ET
Accepted
Feb 3, 8:48 PM ET
Size
22.1 KB
Accession
0001104659-25-008772
Insider Transaction Report
Form 4
Harris Matthew Scott
Chief Medical Officer
Transactions
- Award
Common Stock, par value $0.0001
2025-01-31$5.18/sh+1,905$9,868→ 72,732 total - Exercise/Conversion
Common Stock, par value $0.0001
2025-02-01+6,166→ 78,898 total - Tax Payment
Common Stock, par value $0.0001
2025-02-01$6.64/sh−2,109$14,004→ 76,789 total - Exercise/Conversion
Restricted Stock Units
2025-02-01+6,166→ 0 total→ Common Stock, par value $0.0001 (6,166 underlying) - Tax Payment
Common Stock, par value $0.0001
2025-01-30$7.00/sh−3,173$22,211→ 70,827 total - Tax Payment
Common Stock, par value $0.0001
2025-02-02$6.64/sh−2,708$17,981→ 81,856 total - Exercise/Conversion
Common Stock, par value $0.0001
2025-01-30+9,275→ 74,000 total - Exercise/Conversion
Restricted Stock Units
2025-01-30+9,275→ 18,550 total→ Common Stock, par value $0.0001 (9,275 underlying) - Exercise/Conversion
Common Stock, par value $0.0001
2025-02-02+7,775→ 84,564 total - Exercise/Conversion
Restricted Stock Units
2025-02-02+7,775→ 7,775 total→ Common Stock, par value $0.0001 (7,775 underlying)
Footnotes (7)
- [F1]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.
- [F2]Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs.
- [F3]These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2024 through January 31, 2025.
- [F4]In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on August 1, 2024.
- [F5]The RSUs vest in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.
- [F6]The RSUs vest in substantially equal annual installments over the 4 years following February 1, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.
- [F7]The RSUs vest in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.
Documents
Issuer
Altimmune, Inc.
CIK 0001326190
Entity typeother
Related Parties
1- filerCIK 0001787762
Filing Metadata
- Form type
- 4
- Filed
- Feb 2, 7:00 PM ET
- Accepted
- Feb 3, 8:48 PM ET
- Size
- 22.1 KB